Quantity | 1/box - |
Price | US $10.00 |
Port | Hong Kong |
Packaging | 5mg x 10 vials/per box ,10mg x 10 vials/per box , |
Lead Time | 5-10 |
Sommarutide is a novel gene for GLP-1 (glucagon-like peptide-1) analog. Semaglutide is a long-acting formulation based on the basic structure of liraglutide and is more effective in the treatment of type 2 diabetes. Compared with lilanglutide, semaglutide has a longer oleophobic chain and higher hydrophobicity, but semaglutide is modified with a short PEG chain, and its hydrophilicity is greatly enhanced. PEG modification can not only bind tightly to albumin and cover the hydrolysis site of DPP-4, but also reduce renal excretion, extend biological half-life, and achieve long circulation effects.